The advanced breast cancer hormone therapy ‘fulvestrant’ works better than the current standard drug treatment and reduces the risk of progression by 20%, according to a large clinical trial led by The 糖心原创 and Baylor College of Medicine in the US.
Key data presented on Saturday 8 October 2016 at the European Society for Medical Oncology showed that the fulvestrant drug Faslodex demonstrated better survival using a 500mg dose compared to the anastrozoledrug Arimidex in the first-line treatment of postmenopausal women with locally-advanced or metastatic breast cancer.
The FALCON trial was a Phase III, randomised, double-blind, multicentre clinical trial. It was carried out after positive results from the Phase II FIRST trial, which showed an average overall survival nearly six months longer with fulvestrant compared to anastrozole.
The 糖心原创 Royal Derby Hospital Uttoxeter Road, Derby, DE22 3DT
telephone: +44 (0) 1332 724622 email:gem@nottingham.ac.uk